Published in Eur Arch Psychiatry Clin Neurosci on May 15, 2014
Schizophrenia spectrum and related neuropathology. Eur Arch Psychiatry Clin Neurosci (2015) 0.75
GSK3 takes centre stage more than 20 years after its discovery. Biochem J (2001) 7.74
The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol (2001) 6.12
Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat Genet (2004) 4.71
Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol Psychiatry (2004) 3.90
Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem Res (2006) 3.12
Regulation of mouse brain glycogen synthase kinase-3 by atypical antipsychotics. Int J Neuropsychopharmacol (2006) 2.19
In vivo regulation of glycogen synthase kinase-3beta (GSK3beta) by serotonergic activity in mouse brain. Neuropsychopharmacology (2004) 1.73
Olanzapine impairs glycogen synthesis and insulin signaling in L6 skeletal muscle cells. Mol Psychiatry (2005) 1.55
Antipsychotics alter the protein expression levels of beta-catenin and GSK-3 in the rat medial prefrontal cortex and striatum. Biol Psychiatry (2005) 1.41
Glycogen synthase kinase-3 regulates microglial migration, inflammation, and inflammation-induced neurotoxicity. Cell Signal (2008) 1.41
Neuroinflammation: the role and consequences. Neurosci Res (2013) 1.26
Inhibition of glycogen synthase kinase 3beta (GSK3beta) decreases inflammatory responses in brain endothelial cells. Am J Pathol (2010) 1.17
Low GSK-3beta immunoreactivity in postmortem frontal cortex of schizophrenic patients. Am J Psychiatry (2000) 1.07
Psychotropic drugs affect Ser9-phosphorylated GSK-3 beta protein levels in rodent frontal cortex. Int J Neuropsychopharmacol (2005) 1.05
Olanzapine: a basic science update. Br J Psychiatry Suppl (1999) 0.98
Glycogen synthase kinase-3beta immunoreactivity is reduced in the prefrontal cortex in schizophrenia. Neurosci Lett (2001) 0.96
Glycogen synthase kinase-3 inhibitors: Rescuers of cognitive impairments. Pharmacol Ther (2013) 0.94
Glycogen Synthase Kinase-3 is an Intermediate Modulator of Serotonin Neurotransmission. Front Mol Neurosci (2011) 0.90
Increased platelet GSK3B activity in patients with mild cognitive impairment and Alzheimer's disease. J Psychiatr Res (2010) 0.89
GSK-3 parameters in postmortem frontal cortex and hippocampus of schizophrenic patients. Schizophr Res (2004) 0.88
GSK-3 parameters in lymphocytes of schizophrenic patients. Psychiatry Res (2002) 0.87
Association of GSK-3β genetic variation with GSK-3β expression, prefrontal cortical thickness, prefrontal physiology, and schizophrenia. Am J Psychiatry (2013) 0.87
Activation of the JAK-STAT pathway by olanzapine is necessary for desensitization of serotonin2A receptor-stimulated phospholipase C signaling in rat frontal cortex but not serotonin2A receptor-stimulated hormone release. J Psychopharmacol (2009) 0.86
Chronic olanzapine activates the Stat3 signal transduction pathway and alters expression of components of the 5-HT2A receptor signaling system in rat frontal cortex. Neuropharmacology (2007) 0.86
Serotonin and its receptors in the human CNS with new findings - a mini review. Curr Med Chem (2011) 0.81
GSK-3beta in cerebrospinal fluid of schizophrenia patients. J Neural Transm (Vienna) (2004) 0.81
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry (2010) 4.85
Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry (2010) 2.98
The neurobiology of the switch process in bipolar disorder: a review. J Clin Psychiatry (2010) 1.94
Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine. Neuropsychopharmacology (2010) 1.65
Mental disorders in megacities: findings from the São Paulo megacity mental health survey, Brazil. PLoS One (2012) 1.56
Glutamatergic modulators: the future of treating mood disorders? Harv Rev Psychiatry (2010) 1.42
Dynamic regulation of mitochondrial function by glucocorticoids. Proc Natl Acad Sci U S A (2009) 1.38
A potential role for pro-inflammatory cytokines in regulating synaptic plasticity in major depressive disorder. Int J Neuropsychopharmacol (2009) 1.28
Novel insights into lithium's mechanism of action: neurotrophic and neuroprotective effects. Neuropsychobiology (2010) 1.25
Comparison of repetitive transcranial magnetic stimulation and electroconvulsive therapy in unipolar non-psychotic refractory depression: a randomized, single-blind study. Int J Neuropsychopharmacol (2006) 1.20
The role of hippocampal GluR1 and GluR2 receptors in manic-like behavior. J Neurosci (2008) 1.19
Effect of brain-derived neurotrophic factor Val66Met polymorphism and serum levels on the progression of mild cognitive impairment. World J Biol Psychiatry (2010) 1.12
A kinesin signaling complex mediates the ability of GSK-3beta to affect mood-associated behaviors. Proc Natl Acad Sci U S A (2010) 1.11
Increased serum IL-1beta level in Alzheimer's disease and mild cognitive impairment. Dement Geriatr Cogn Disord (2009) 1.10
Does lithium prevent Alzheimer's disease? Drugs Aging (2012) 1.10
Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depression. Prog Neuropsychopharmacol Biol Psychiatry (2011) 1.09
Glutamate receptors as targets of protein kinase C in the pathophysiology and treatment of animal models of mania. Neuropharmacology (2008) 1.07
Effects of lithium on oxidative stress parameters in healthy subjects. Mol Med Rep (2011) 1.05
Lithium reduces Gsk3b mRNA levels: implications for Alzheimer Disease. Eur Arch Psychiatry Clin Neurosci (2008) 1.03
Increased uric acid levels in drug-naïve subjects with bipolar disorder during a first manic episode. Prog Neuropsychopharmacol Biol Psychiatry (2010) 1.03
The detection of depression in medical setting: a study with PRIME-MD. J Affect Disord (2006) 1.00
Clinical predictors of ketamine response in treatment-resistant major depression. J Clin Psychiatry (2014) 1.00
Reduced serum nerve growth factor in patients with late-life depression. Am J Geriatr Psychiatry (2013) 0.98
The use of ASB-14 in combination with CHAPS is the best for solubilization of human brain proteins for two-dimensional gel electrophoresis. Brief Funct Genomic Proteomic (2007) 0.97
An investigation of amino-acid neurotransmitters as potential predictors of clinical improvement to ketamine in depression. Int J Neuropsychopharmacol (2011) 0.97
Profiles of functional deficits in mild cognitive impairment and dementia: benefits from objective measurement. J Int Neuropsychol Soc (2010) 0.96
Lithium and neuroprotection: translational evidence and implications for the treatment of neuropsychiatric disorders. Neuropsychiatr Dis Treat (2013) 0.95
Developing biomarkers in mood disorders research through the use of rapid-acting antidepressants. Depress Anxiety (2013) 0.95
Does gene deletion of AMPA GluA1 phenocopy features of schizoaffective disorder? Neurobiol Dis (2010) 0.94
D-serine plasma concentration is a potential biomarker of (R,S)-ketamine antidepressant response in subjects with treatment-resistant depression. Psychopharmacology (Berl) (2014) 0.93
Recognition of depressive symptoms by physicians. Clinics (Sao Paulo) (2009) 0.93
Lithium increases plasma brain-derived neurotrophic factor in acute bipolar mania: a preliminary 4-week study. Neurosci Lett (2011) 0.93
Increased soluble TNF receptor 2 in antidepressant-free patients with late-life depression. J Psychiatr Res (2010) 0.91
Serum brain-derived neurotrophic factor level is reduced in antidepressant-free patients with late-life depression. World J Biol Psychiatry (2010) 0.91
Disabling hearing loss prevalence in Juiz de Fora, Brazil. Braz J Otorhinolaryngol (2012) 0.90
Rapid antidepressant changes with sleep deprivation in major depressive disorder are associated with changes in vascular endothelial growth factor (VEGF): a pilot study. Brain Res Bull (2011) 0.89
Targeting mitochondrially mediated plasticity to develop improved therapeutics for bipolar disorder. Expert Opin Ther Targets (2014) 0.89
Bax inhibitor 1, a modulator of calcium homeostasis, confers affective resilience. Brain Res (2011) 0.88
Use of psychoactive substances and sexual risk behavior in adolescents. Subst Use Misuse (2002) 0.88
Higher serum sTNFR1 level predicts conversion from mild cognitive impairment to Alzheimer's disease. J Alzheimers Dis (2010) 0.88
Physical exercise in MCI elderly promotes reduction of pro-inflammatory cytokines and improvements on cognition and BDNF peripheral levels. Curr Alzheimer Res (2014) 0.87
The immunology of bipolar disorder. Neuroimmunomodulation (2014) 0.87
The more information, the more negative stigma towards schizophrenia: Brazilian general population and psychiatrists compared. Psychiatry Res (2012) 0.86
Interleukin-1beta serum levels is increased in antidepressant-free elderly depressed patients. Am J Geriatr Psychiatry (2010) 0.85
Inhibitory effects of resveratrol analogs on mushroom tyrosinase activity. Molecules (2012) 0.85
Diagnostic transitions in mild cognitive impairment subtypes. Int Psychogeriatr (2009) 0.85
31P-spectroscopy of frontal lobe in schizophrenia: alterations in phospholipid and high-energy phosphate metabolism. Schizophr Res (2002) 0.84
Salivary alpha-amylase activity: a possible indicator of pain-induced stress in orthodontic patients. Pain Med (2011) 0.84
Bcl-2 rs956572 polymorphism is associated with increased anterior cingulate cortical glutamate in euthymic bipolar I disorder. Neuropsychopharmacology (2012) 0.84
Number of manic episodes is associated with elevated DNA oxidation in bipolar I disorder. Int J Neuropsychopharmacol (2013) 0.83
Association of the COMT Met¹⁵⁸ allele with trait impulsivity in healthy young adults. Mol Med Rep (2013) 0.83
The impact of the CACNA1C risk allele on limbic structures and facial emotions recognition in bipolar disorder subjects and healthy controls. J Affect Disord (2012) 0.83
Azastilbene analogs as tyrosinase inhibitors: new molecules with depigmenting potential. ScientificWorldJournal (2013) 0.83
To treat or not to treat? A meta-analysis of the use of cholinesterase inhibitors in mild cognitive impairment for delaying progression to Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci (2009) 0.83
Cognitive dysfunction in depression - pathophysiology and novel targets. CNS Neurol Disord Drug Targets (2014) 0.83
Vocational rehabilitation improves cognition and negative symptoms in schizophrenia. Schizophr Res (2010) 0.83
Aripiprazole for patients with schizophrenia and schizoaffective disorder: an open-label, randomized, study versus haloperidol. CNS Spectr (2009) 0.82
Platelet GSK3B activity in patients with late-life depression: marker of depressive episode severity and cognitive impairment? World J Biol Psychiatry (2011) 0.81
A proton magnetic resonance spectroscopy investigation of the dorsolateral prefrontal cortex in acute mania. Hum Psychopharmacol (2005) 0.81
BDNF blood levels after electroconvulsive therapy in patients with mood disorders: a systematic review and meta-analysis. World J Biol Psychiatry (2014) 0.81
Language impairment in euthymic, elderly patients with bipolar disorder but no dementia. Int Psychogeriatr (2008) 0.81
Stigma toward schizophrenia: do all psychiatrists behave the same? Latent profile analysis of a national sample of psychiatrists in Brazil. BMC Psychiatry (2013) 0.81
Leukocyte mitochondrial DNA copy number in bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry (2013) 0.81
Lithium increases leukocyte mitochondrial complex I activity in bipolar disorder during depressive episodes. Psychopharmacology (Berl) (2014) 0.81
Novel biomarkers for bipolar disorder. Expert Opin Med Diagn (2012) 0.81
SHORT COMMUNICATION: Apolipoprotein E genotype and cognition in bipolar disorder. CNS Neurosci Ther (2010) 0.80
Polydimethylsiloxane: a new contrast material for localization of occult breast lesions. Radiol Oncol (2011) 0.80
COMT Met (158) modulates facial emotion recognition in bipolar I disorder mood episodes. J Affect Disord (2012) 0.79
Cytokines plasma levels during antidepressant treatment with sertraline and transcranial direct current stimulation (tDCS): results from a factorial, randomized, controlled trial. Psychopharmacology (Berl) (2013) 0.79
Relative bioavailability of two oral formulations of risperidone 2 mg: A single-dose, randomized-sequence, open-label, two-period crossover comparison in healthy Brazilian volunteers. Clin Ther (2010) 0.79
Long-term decrease in immediate early gene expression after electroconvulsive seizures. J Neural Transm (Vienna) (2012) 0.78
Increased plasma levels of soluble TNF receptors 1 and 2 in bipolar depression and impact of lithium treatment. Hum Psychopharmacol (2015) 0.78
COMT polymorphisms as predictors of cognitive dysfunction during manic and mixed episodes in bipolar I disorder. Bipolar Disord (2012) 0.78
Allelic association analysis of phospholipase A2 genes with schizophrenia. Psychiatr Genet (2004) 0.78
Gender effects of the COMT Val 158 Met genotype on verbal fluency in healthy adults. Mol Med Rep (2013) 0.78
Therapeutic Modulation of Glutamate Receptors in Major Depressive Disorder. Curr Neuropharmacol (2017) 0.78
Assessment of pain experience in adults and children after bracket bonding and initial archwire insertion. Dental Press J Orthod (2013) 0.77
Photoprotective activity of resveratrol analogues. Bioorg Med Chem (2012) 0.77
Cognitive-linguistic deficits in euthymic elderly patients with bipolar disorder. J Affect Disord (2013) 0.77
Reduced activities of phospholipases A2 in platelets of drug-naïve bipolar disorder patients. Bipolar Disord (2014) 0.77
Lower Cerebrospinal Fluid Concentration of Brain-Derived Neurotrophic Factor Predicts Progression from Mild Cognitive Impairment to Alzheimer's Disease. Neuromolecular Med (2015) 0.77
[Neuropatological and neurochemical abnormalities in bipolar disorder]. Rev Bras Psiquiatr (2004) 0.77
Current pharmacological approaches and perspectives in the treatment of geriatric mood disorders. Curr Opin Psychiatry (2011) 0.76
Does BDNF genotype influence creative output in bipolar I manic patients? J Affect Disord (2012) 0.76
Synaptic plasticity in the pathophysiology and treatment of bipolar disorder. Curr Top Behav Neurosci (2011) 0.76
The impact of limbic system morphology on facial emotion recognition in bipolar I disorder and healthy controls. Neuropsychiatr Dis Treat (2013) 0.76
BDNF blood levels after non-invasive brain stimulation interventions in major depressive disorder: a systematic review and meta-analysis. World J Biol Psychiatry (2014) 0.76
Antipsychotic drugs decrease iPLA2 gene expression in schizophrenia. Schizophr Res (2013) 0.76